Beta Bionics and Zealand Pharma initiate home-use trial of the iLet™ bionic pancreas with dasiglucagon for autonomous bihormonal treatment of Type 1 diabetes First home-use trial of the bihormonal ...
The trial achieved key primary and secondary endpoints, demonstrating improved outcomes over standard of care for people living with type 1 diabetes. The study population — 440 adults and children 6 ...
The investigational insulin-only iLet Bionic Pancreas (Beta Bionics) reduced A1c without increasing hypoglycemia in adults and children with type 1 diabetes with greater automation than currently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback